At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 87 enrolled
Drug / intervention
Dalteparindrug
Likely dose
Dalteparin 5000 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.
In Brief
A Phase 4 clinical trial evaluating Dalteparin for Pancreatic Cancer and Venous Thromboembolism. Completed, enrolled 87 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy. Some patients will receive dalteparin and some will receive no study drug. The safety of dalteparin will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Venous Thromboembolism
CountriesUnited States
CollaboratorsEisai Inc.
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartApr 2010
Primary CompletionSep 2014
TodayJul 2026
First PostedAug 26, 2009
Enrollment StartApr 1, 2010
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.8 years ago
Interventions
Dalteparindrug
5000 units subcutaneous, by injection under the skin, daily for 16 weeks